Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic/Colorectal Cancer (Macrobead)
An Open-Label Phase 2 Efficacy Trial of the Implantation of Mouse Renal Adenocarcinoma Cell-Containing Agarose-Agarose Macrobeads in the Treatment of Patients With Treatment-Resistant, Metastatic Pancreatic or Colorectal Cancer
Sponsor: The Rogosin Institute
A PHASE2 clinical study on Colorectal Cancer Metastatic and Pancreatic Adenocarcinoma Metastatic, this trial is completed. The trial is conducted by The Rogosin Institute and has accumulated 16 data snapshots since 2010. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
16 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
-
Dec 2021 — Dec 2022 [monthly]
Completed PHASE2
▶ Show 11 earlier versions
-
Jun 2021 — Dec 2021 [monthly]
Completed PHASE2
-
May 2021 — Jun 2021 [monthly]
Completed PHASE2
-
Jan 2021 — May 2021 [monthly]
Completed PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Apr 2020 — Dec 2020 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jul 2019 — Apr 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2019 — Jul 2019 [monthly]
Recruiting PHASE2
-
Nov 2018 — Feb 2019 [monthly]
Recruiting PHASE2
-
Jun 2018 — Nov 2018 [monthly]
Recruiting PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Apr 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- The Rogosin Institute
- Vital Systems Inc.
For direct contact, visit the study record on ClinicalTrials.gov .